{"id":923212,"date":"2026-07-09T13:09:35","date_gmt":"2026-07-09T13:09:35","guid":{"rendered":"https:\/\/www.europesays.com\/us\/923212\/"},"modified":"2026-07-09T13:09:35","modified_gmt":"2026-07-09T13:09:35","slug":"fort-worths-omnicell-names-chief-operating-officer-as-president-dallas-innovates","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/923212\/","title":{"rendered":"Fort Worth\u2019s Omnicell Names Chief Operating Officer as President \u00bb Dallas Innovates"},"content":{"rendered":"

\"Nnamdi<\/p>\n

Nnamdi Njoku is president and COO of Omnicell. [Photo: Omnicell]<\/p>\n

Omnicell Inc., a Fort Worth-based healthcare tech company that offers autonomous medication management, has appointed Chief Operating Officer Nnamdi Njoku as the company\u2019s president.<\/p>\n

Njoku will retain his role as COO, while Randall Lipps will continue to serve as CEO and chairman, focusing on strategic collaborations and the long-term evolution of Omnicell\u2019s portfolio.<\/p>\n

In his newly combined roles, Njoku will lead Omnicell\u2019s long-term growth strategy and innovation plans, the company said. This includes scaling global operations and working to ensure seamless operational execution and excellence across product, innovation and customer experience. He will also continue to advance pivotal business initiatives including the launch of the Omnicell Titan XT automated dispensing system and the expansion of the cloud-native OmniSphere platform.<\/p>\n

\u201cSince joining Omnicell in 2024, Nnamdi has made a significant strategic impact on the company, working to strengthen our operational foundation, shape our strategic direction and organizational design, and build strong relationships with our customers and the investment community,\u201d Lipps said in a statement<\/a>. \u201cNnamdi is a proven leader who brings clarity, discipline and precision to our efforts to scale our business and accelerate momentum for our strategy.\u201d<\/p>\n

He added that the appointment represents a logical next step in the company\u2019s leadership structure, allowing Lipps \u201cto be laser-focused on strategic customer and industry relationships, the evolution of our solution offerings, and our long-term vision.\u201d<\/p>\n

Expertise in operational growth<\/strong><\/p>\n

Before joining Omnicell<\/a>, Njoku spent more than 18 years in various executive leadership roles at Medtronic plc, including serving as senior vice president and president of the Neuromodulation Operating Unit. This approximately $2 billion business uses neuromodulation to treat conditions such as pain and movement disorders. Previously, Njoku held operational roles of increasing responsibility at Zimmer Biomet Holdings Inc., UnitedHealth Group and Deloitte Consulting.<\/p>\n

\u201cAs care delivery grows more distributed and complex, and financial and operational pressures intensify, we believe healthcare leaders need a trusted partner focused on delivering the innovation and intelligence that drives real outcomes,\u201d Njoku said. \u201cI\u2019m excited to lead Omnicell through our next planned phase of growth as we strive to scale the business and execute on our strategy to transform our customers\u2019 clinical and operational performance.\u201d<\/p>\n

Njoku is a fellow of the fourth class of Aspen Institute\u2019s Health Innovators Fellowship and a member of the Aspen Global Leadership Network.<\/p>\n

Don\u2019t miss what\u2019s next. Subscribe\u00a0to\u00a0Dallas\u00a0Innovates.<\/p>\n

Track Dallas-Fort Worth\u2019s business and innovation landscape with our curated news in your inbox Tuesday-Thursday.<\/p>\n

\u00a0<\/p>\n

\tR E A D\u00a0\u00a0 N E X T\t<\/p>\n